[{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Private Placement","leadProduct":"Durvalumab","moa":"||Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Immunocore \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ RTW Investments"},{"orgOrder":0,"company":"Immunocore","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Immunocore","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Immunocore"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Medison Pharma"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Blackrock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Series C Financing","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Blackrock","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Blackrock"},{"orgOrder":0,"company":"Immunocore","sponsor":"EORTC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ EORTC","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ EORTC"},{"orgOrder":0,"company":"Immunocore","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Public Offering","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Partnership","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Medison Pharma"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"||PRAME","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"Brenetafusp","moa":"||PRAME","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Immunocore","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore \/ Immunocore"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Immunocore","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Immunocore","highestDevelopmentStatusID":"8","companyTruncated":"Immunocore \/ Immunocore"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMC-I109V","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IMC-I109V","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMC-C103C","moa":"||MAGE-A4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Genentech"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"SAR444245","moa":"||IL-2R beta\/gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Sanofi"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMC-I109V","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMC-M113V","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Clinigen Group"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Melanocyte protein PMEL","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Immunocore","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Immunocore","highestDevelopmentStatusID":"8","companyTruncated":"Immunocore \/ Immunocore"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"IMC-R117C","moa":"PIWIL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMC-R117C","moa":"PIWIL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"MAGE-A4","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ General Atlantic"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMC-P115C","moa":"PRAME\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Gadeta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"GDT201","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Gadeta","highestDevelopmentStatusID":"4","companyTruncated":"Immunocore \/ Gadeta"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Erkim"}]
Find Clinical Drug Pipeline Developments & Deals by Immunocore
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
